DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
Status:
Completed
Trial end date:
2018-03-15
Target enrollment:
Participant gender:
Summary
Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant
primary brain tumor in adults and can be resistant to conventional therapies. The purpose of
this Phase Ib study is to evaluate how well a recurrent glioblastoma or gliosarcoma tumor
responds to one injection of DNX-2401, a genetically modified, conditionally replicative and
oncolytic human-derived adenovirus. DNX-2401 is delivered directly into the tumor where it
may establish an active infection by replicating in and killing tumor cells.